INOVIQ (IIQ) Stock Overview
Develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
IIQ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
INOVIQ Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.40 |
| 52 Week High | AU$0.69 |
| 52 Week Low | AU$0.34 |
| Beta | 1.81 |
| 1 Month Change | 8.11% |
| 3 Month Change | -9.09% |
| 1 Year Change | -31.03% |
| 3 Year Change | -29.82% |
| 5 Year Change | -54.02% |
| Change since IPO | -44.44% |
Recent News & Updates
Recent updates
We're Not Very Worried About INOVIQ's (ASX:IIQ) Cash Burn Rate
Jun 10
We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth
Apr 22A Look At The Intrinsic Value Of INOVIQ Ltd (ASX:IIQ)
Mar 01We Think Shareholders May Want To Consider A Review Of INOVIQ Ltd's (ASX:IIQ) CEO Compensation Package
Nov 22Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth
Jun 21Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth
Feb 16INOVIQ (ASX:IIQ) Is In A Good Position To Deliver On Growth Plans
Sep 28We're Hopeful That INOVIQ (ASX:IIQ) Will Use Its Cash Wisely
Jun 08We're Keeping An Eye On INOVIQ's (ASX:IIQ) Cash Burn Rate
Jan 28Are Insiders Selling BARD1 Life Sciences Limited (ASX:BD1) Stock?
Mar 02Don't Ignore The Fact That This Insider Just Sold Some Shares In BARD1 Life Sciences Limited (ASX:BD1)
Mar 02BARD1 Life Sciences (ASX:BD1) Is In A Good Position To Deliver On Growth Plans
Dec 28Shareholder Returns
| IIQ | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | -2.4% | -3.3% | 0.2% |
| 1Y | -31.0% | -10.8% | 11.4% |
Return vs Industry: IIQ underperformed the Australian Healthcare industry which returned -10.8% over the past year.
Return vs Market: IIQ underperformed the Australian Market which returned 11.4% over the past year.
Price Volatility
| IIQ volatility | |
|---|---|
| IIQ Average Weekly Movement | 12.9% |
| Healthcare Industry Average Movement | 6.6% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in AU Market | 18.9% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: IIQ has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: IIQ's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Leearne Hinch | www.inoviq.com |
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of cancer and other diseases.
INOVIQ Ltd Fundamentals Summary
| IIQ fundamental statistics | |
|---|---|
| Market cap | AU$44.65m |
| Earnings (TTM) | -AU$6.93m |
| Revenue (TTM) | AU$1.82m |
Is IIQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IIQ income statement (TTM) | |
|---|---|
| Revenue | AU$1.82m |
| Cost of Revenue | AU$3.37m |
| Gross Profit | -AU$1.56m |
| Other Expenses | AU$5.37m |
| Earnings | -AU$6.93m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.062 |
| Gross Margin | -85.91% |
| Net Profit Margin | -381.88% |
| Debt/Equity Ratio | 1.3% |
How did IIQ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/25 08:29 |
| End of Day Share Price | 2025/08/25 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
INOVIQ Ltd is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chris Kallos | MST Financial Services Pty Limited |